Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer
复制标题
DOI：
10.1136/jcp.2010.082966
复制
发表时间：
2011-02-01
影响因子：
3.4
通讯作者：
Albanell, Joan
中科院分区：
文献类型：
--
作者：
Jones, Robin L.;Rojo, Federico;Albanell, Joan
目的评价转录因子核因子-kappaB在乳腺癌新辅助化疗患者中的临床病理相关性和预测价值。结果26.3%(35/133)的乳腺癌组织中有核转录因子-kappaB的表达。核转录因子-kappaB表达与高组织学分级、雌激素受体(ER)阴性及Ki67指数升高有关(P=0.002)。核转录因子-kappaB阳性患者的病理完全缓解率(26.5%)明显高于核阴性患者(6.0%，p=0.004)，与临床疗效及预后无明显相关性。在探索性假设生成分析中，在ER+/HER2-亚组(n=43)中，核因子-kappaB染色的患者的临床缓解率显著低于核因子-kappaB染色的患者(14.3%vs61.0%，p=0.038)。结论核转录因子-kappaB的表达与ER阴性、Ki67指数高及肿瘤分级有关。研究还发现，这与新辅助化疗的PCR值升高有关，但与临床反应无关。
Aims To evaluate the clinicopathological associations and predictive value of the transcription factor NF-kappa B in a large series of breast cancer patients treated with neoadjuvant chemotherapy.Methods A retrospective search of a prospectively maintained database was performed to identify patients. Immunohistochemistry was used to assess the p65 subunit of NF-kappa B, using nuclear staining as a surrogate of activation.Results Nuclear NF-kappa B expression was found in 26.3% (35/133) of cases. Nuclear NF-kappa B staining was associated with high histological grade (p=0.05), oestrogen receptor (ER) negativity (p=0.01) and higher Ki67 index (p=0.002). Patients with nuclear NF-kappa B staining had a higher pathological complete response (pCR) rate than those without (26.5% vs 6.0% respectively, p=0.004); there was no significant association with clinical response or outcome. In an exploratory hypothesis-generating analysis, in the ER+/HER2- subgroup (n=43) a significantly lower clinical response rate was observed in those with nuclear NF-kappa B staining compared with those who had no nuclear NF-kappa B staining (14.3% vs 61.0%, p=0.038). There were no pCRs in ER+/HER2- tumours.Conclusions Nuclear NF-kappa B expression is associated with ER negativity, higher Ki67 index and tumour grade. It was also found to be significantly associated with increased pCR but not clinical response to neoadjuvant chemotherapy.